In a groundbreaking case series published in BMC Psychiatry, researchers have shed new light on the therapeutic potential of aripiprazole monotherapy for patients grappling not only with bipolar disorder (BD) but also the notoriously challenging condition known as delayed sleep-wake phase (DSWP) syndrome. This pioneering study delves deep into an area that has long lacked robust clinical guidance, offering compelling insights into how aripiprazole could mechanism-wise advance circadian rhythm normalization while mitigating psychiatric symptoms.
Bipolar disorder, a mood disorder characterized by oscillating episodes of mania and depression, poses significant challenges in treatment, especially when complicated by sleep rhythm disruptions. DSWP syndrome is typified by a marked delay in the sleep cycle, often leading to sleeping and waking times that are incompatible with societal norms. Prior research has indicated that patients exhibiting this overlapping symptomatology tend to be younger, are susceptible to more frequent relapses, and suffer from a pronounced decline in social functioning.
The study conducted a meticulous chart review of 15 individuals clinically diagnosed with both BD and DSWP, who underwent treatment solely with aripiprazole over a duration ranging from 12 weeks up to an astonishing 135 weeks. The selection of aripiprazole—a dopamine partial agonist with unique mechanism of action influencing multiple neurotransmitter systems—stems from its distinct pharmacodynamic profile that potentially resynchronizes disrupted circadian patterns while stabilizing mood fluctuations.
Notably, within just two weeks of initiating treatment, patients demonstrated significant improvements, as measured by reductions in the Clinical Global Impressions-Severity (CGI-S) scale—a gold standard for assessing illness severity in psychiatric disorders. These early changes were accompanied by a noteworthy phase advancement in sleep-wake cycles, indicating that aripiprazole was not only exerting psychotropic effects but also modulating fundamental circadian mechanisms.
By the endpoint of the study, an impressive 93.3% of participants achieved clinical remission, operationally defined as attaining a CGI-S score below 3. This marked improvement was paralleled by substantial recovery in social functioning, reinforcing the bidirectional relationship between effective pharmacotherapy and quality of life enhancements. Such results underscore the importance of addressing circadian misalignment directly in the context of BD management.
Safety profiles are paramount in long-term psychiatric treatments, and this case series reported that while extrapyramidal symptoms and weight gain were among the most frequently encountered adverse effects, these were reversible upon appropriate management. The transient nature of these side effects suggests that aripiprazole’s therapeutic benefits can be harnessed without compromising patient well-being, an essential consideration for chronic conditions requiring sustained intervention.
Mechanistically, aripiprazole’s dopamine partial agonism is posited to stabilize dopaminergic neurotransmission, which is intimately linked to circadian regulation pathways. Moreover, its serotonergic activity may further contribute to altering sleep architecture, facilitating the phase advancement necessary for correcting DSWP. This dual action provides a plausible biological rationale for the observed clinical improvements and prompts further investigation into aripiprazole’s chronotherapeutic potential.
This study’s retrospective design and relatively small sample size warrant caution in generalizing findings, yet the compelling efficacy and safety outcomes herald a promising avenue for future randomized controlled trials. The authors advocate for systematic clinical investigations that could ultimately refine treatment guidelines for BD comorbid with circadian rhythm disruptions, an area critically underserved in psychiatric research.
The intersection of bipolar disorder and DSWP syndrome has traditionally been a thorny clinical challenge due to the paucity of targeted interventions and the complex neurobiological underpinnings involved. By illuminating the role of aripiprazole monotherapy, this research bridges a critical gap, offering a beacon of hope for patients whose symptoms have historically been refractory to conventional therapies.
Furthermore, the potential societal implications of successfully treating DSWP in bipolar patients could be substantial. Early remission and social reintegration can diminish the socioeconomic burden associated with recurrent psychiatric hospitalizations and disability. This study underscores the broader importance of considering circadian biology in neuropsychiatric disorder management.
As aripiprazole is already widely used in clinical psychiatry, repurposing it with a focus on circadian rhythm disorders in bipolar populations could expedite translational applications. The findings propel the conversation about integrated chronopharmacology approaches—therapies tailored not only to mood symptoms but also to the fundamental biological rhythms underpinning mental health.
In sum, the case series authored by Li and colleagues charts an encouraging path forward for a subset of bipolar disorder patients often overlooked in research and clinical practice. Their work suggests that aripiprazole monotherapy may fulfill dual roles: stabilizing mood and realigning the sleep-wake cycle—with significant implications for both symptom remission and quality of life.
The neuropsychiatric community eagerly anticipates follow-up investigations to validate these preliminary observations, explore optimal dosing strategies, and delineate long-term outcomes. Ultimately, embracing circadian-informed pharmacotherapy might redefine standards of care and open new therapeutic horizons in mental health.
Subject of Research: Bipolar disorder with delayed sleep-wake phase syndrome treatment using aripiprazole monotherapy.
Article Title: Case series of aripiprazole monotherapy in bipolar disorder with delayed sleep-wake phase syndrome.
Article References:
Li, T., Yang, T., Lin, Y. et al. Case series of aripiprazole monotherapy in bipolar disorder with delayed sleep-wake phase syndrome. BMC Psychiatry 25, 899 (2025). https://doi.org/10.1186/s12888-025-07289-y
Image Credits: AI Generated
